# What Is KLOW Peptide? A Plain-English Overview > What is KLOW peptide? A plain-English overview of the four-component research blend — KPV, GHK-Cu, BPC-157, and TB-500 — including what each component does, its research status, and the key caveats. Four peptides, one research vial. A plain-language specification of what each arm is, what the literature says it does, and what has never been tested. ## What is KLOW peptide — the short version KLOW peptide is a blend of four distinct compounds — KPV, GHK-Cu, BPC-157, and TB-500 — combined in a single research vial. You can think of it as four research peptides packaged together because each one targets a different step in how the body manages repair and inflammation. Each component has its own published science, mostly from animal studies and cell experiments. None of them is FDA-approved for human use. The blend as a whole has never been tested in any controlled study — meaning that claims about 'what KLOW does' are always an educated guess based on each ingredient's separate track record, not a documented result of the four being combined. The most important practical quirk: the four peptides clear the body at different speeds, so a single dose can't keep all four active at the same time. That's the pharmacokinetic mismatch this site treats as a structural feature of the blend. What is KLOW peptide, in sum: four research-only compounds in one vial, with a coherent mechanistic rationale and an empty combination-trial file. ## What is KLOW peptide — the four components explained **KPV (Lys-Pro-Val) — anti-inflammatory arm.** KPV is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring regulatory peptide. In cell studies and mouse colitis models, nanomolar KPV inhibits NF-kappaB (the master switch for inflammatory gene transcription) and reduces pro-inflammatory signals including TNF-alpha, IL-6, and IL-1beta [3]. Its primary route into cells is through PepT1 (SLC15A1, the di/tripeptide transporter), which is upregulated in inflamed gut tissue, giving KPV a tissue-selective uptake profile. KPV is the fourth peptide in KLOW — not present in the related GLOW blend — and is the arm most frequently credited in community accounts for anti-inflammatory and gut-comfort benefits. **GHK-Cu (Gly-His-Lys Copper(II)) — matrix-and-copper arm.** GHK-Cu is a naturally occurring tripeptide-copper complex; plasma levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4]. It is the mass-dominant component of the KLOW vial at 50 of the 80 mg (62.5%). GHK-Cu drives collagen synthesis and extracellular-matrix gene expression in fibroblasts, and a 2018 analysis showed it modulates approximately 31.2% of human genes at a ≥50% change threshold, with strong signals on tissue repair, DNA repair, and antioxidant programs [5]. Topical GHK-Cu has the best human evidence in the blend (placebo-controlled cosmetic and wound data [4]), including ex-vivo skin penetration studies confirming a transdermal copper depot [10]. **BPC-157 (Body Protection Compound 157) — angiogenic-repair arm.** BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein in gastric juice. Its principal action is activation of the VEGFR2 angiogenic signaling cascade, which promotes new blood-vessel formation in damaged tissue. In rats with fully transected Achilles tendons, BPC-157 at doses as low as 10 pg per rat accelerated healing across biomechanical, functional, and histological measures [2]. It also modulates the nitric-oxide (NO) system via a route partly resistant to L-NAME. The human BPC-157 record is sparse: a 2025 IV pilot in two adults found it well tolerated at 10–20 mg [6], and a 2026 fistula study reported NO-system-mediated resolution in rats [14]. BPC-157 is FDA 503A category 2. **TB-500 (Ac-LKKTETQ) — cytoskeletal arm.** TB-500 is a short synthetic peptide corresponding to the actin-binding region of thymosin beta-4 (Tbeta4), a 43-amino-acid naturally occurring protein. The LKKTET motif sequesters G-actin (monomeric actin), which influences cell migration and wound closure. The foundational efficacy data in the literature are for full-length Tbeta4, not the TB-500 fragment: in rat full-thickness wound models, Tbeta4 increased re-epithelialization by 42% at 4 days and 61% at 7 days [1]. The distinction matters because TB-500 lacks the domains responsible for integrin-linked-kinase activation and epicardial progenitor mobilization documented for native Tbeta4. Additionally, thymosin beta-4 is on the WADA Prohibited List (S2), which means TB-500, as its fragment, implicates anti-doping rules [7, 9]. ## What is KLOW peptide — the combination rationale and its limits The logic behind combining these four peptides is that they address different stages of the same tissue-repair cascade: KPV handles the inflammatory signal, GHK-Cu handles the structural and matrix response, BPC-157 supports the vascular supply, and TB-500 supports cell movement and closure. Four nodes of one network, each covered by a different arm. The limit of that rationale: it has never been tested. No controlled in-vivo or human study has examined the KLOW combination against monotherapy, any subset, or placebo. Every benefit claim for the blend as a whole is an extrapolation from the single-component literature. The pharmacokinetic mismatch compounds this: KPV and GHK-Cu are small tripeptides that clear quickly, while BPC-157 has a reported sub-30-minute rat half-life that still exceeds the tripeptides, and TB-500's clearance in humans is uncharacterized [8]. Co-formulating them at a fixed ratio means they will not be simultaneously active at matched exposures after a single dose. Whether this reduces, amplifies, or neutralizes any putative combination effect is unknown. See the [klow stack](/blend-components) page for the component-by-component specification and the KLOW vs GLOW distinction. --- A cold spec-sheet record of the four-peptide KLOW blend — each component logged to its own study dossier, the combination-trial field left blank because none exists, and no clinic behind the chassis.